Mild behavioral impairment is linked to worse cognition and brain atrophy in Parkinson disease

Eun Jin Yoon1, Zahinoor Ismail1, Alexandru Hanganu1

  • 1From the Department of Clinical Neurosciences (E.J.Y., Z.I., A.H., M.K., T.H., J.C., I.K., J.R.S., D.M., S.F., O.M.) and Departments of Psychiatry and Community Health Sciences (Z.I.), University of Calgary; Hotchkiss Brain Institute (E.J.Y., Z.I., A.H., M.K., T.H., J.C., I.K., J.R.S., D.M., S.F., O.M.), Cumming School of Medicine, Calgary, Alberta; Centre de Recherche (A.H., O.M.), Institut Universitaire de Gériatrie de Montréal; and Department of Psychology (A.H.), University of Montréal, Québec, Canada.

Neurology
|July 20, 2019
PubMed
Abstract

Insights

Mild behavioral impairment (MBI) is linked to cognitive decline and temporal lobe gray matter changes in Parkinson disease (PD). MBI may serve as an early indicator of cognitive impairment and dementia risk in PD patients.

Area of Science:

  • Neuroscience
  • Neurology
  • Psychiatry

Background:

  • Parkinson disease (PD) is a neurodegenerative disorder.
  • Mild behavioral impairment (MBI) is increasingly recognized in PD.
  • The relationship between MBI, cognitive function, and brain structure in PD requires further investigation.

Purpose of the Study:

  • To investigate the association between MBI and cognitive deficits in Parkinson disease.
  • To examine patterns of gray matter changes in the brains of PD patients with and without MBI.
  • To determine if MBI can predict cognitive decline and dementia in PD.

Main Methods:

  • Sixty PD patients and 29 healthy controls underwent cognitive testing and structural MRI.
  • MBI was assessed using the MBI Checklist (MBI-C).
  • PD patients were categorized into high (PD-MBI) and low (PD-noMBI) MBI-C score groups.

Main Results:

  • One-third of PD patients (33.33%) exhibited MBI (PD-MBI group).
  • The PD-MBI group showed significantly poorer cognitive performance across multiple domains compared to controls and PD-noMBI.
  • PD-MBI was associated with middle temporal cortex thinning and volume reduction, correlating with MBI severity.

Conclusions:

  • Cognitive impairment and temporal lobe atrophy in PD-MBI align with posterior cortical circuit deficits.
  • These deficits are linked to an accelerated progression to dementia.
  • MBI may represent an early and significant biomarker for cognitive decline and dementia in Parkinson disease.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.0K
Cognition and Behavior01:23

Cognition and Behavior

Social psychology examines the complex interplay between individual mental processes and social interactions. Historically, the field was divided into two domains: social behavior and social cognition. Researchers focusing on social behavior analyzed actions within social contexts, such as conformity, aggression, or cooperation. Meanwhile, social cognition researchers investigated how people perceive, interpret, and mentally represent their social environments. However, modern perspectives no...
309
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Cognitive Dissonance01:38

Cognitive Dissonance

Social psychologists have documented that feeling good about ourselves and maintaining positive self-esteem is a powerful motivator of human behavior (Tavris & Aronson, 2008). In the United States, members of the predominant culture typically think very highly of themselves and view themselves as good people who are above average on many desirable traits (Ehrlinger, Gilovich, & Ross, 2005). Often, our behavior, attitudes, and beliefs are affected when we experience a threat to our...
36.8K
Causes of Social Behavior II: Cognitive Processes01:15

Causes of Social Behavior II: Cognitive Processes

Cognitive processes affect social behavior by guiding how individuals perceive, interpret, and respond to social stimuli. These mental processes enable individuals to assess others' behaviors, attribute causes to their actions, and form expectations based on past experiences.Causes of Behavior and Social JudgmentsIndividuals determine the causes of others' behaviors by distinguishing between personal traits and external circumstances. For example, if a friend frequently arrives late, an...
196
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
260